Neuroblastoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
| Line 21: | Line 21: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Revision as of 02:59, 27 November 2017
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma other imaging findings |
|
Risk calculators and risk factors for Neuroblastoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Other imaging studies for neuroblastoma include nuclear medicine studies such as fludeoxyglucose-18F positron emission tomography scan (18F-FDG) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[1]
Other Imaging Findings
Nuclear medicine
- Nuclear medicine studies used for diagnosis of neuroblastoma include fludeoxyglucose-18F positron emission tomography (18F-FDG PET) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[1]
- 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy may distinguish stage 3 and 4 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy is superior than 18F-FDG PET scan in detecting bone marrow metastases.
References
- ↑ 1.0 1.1 Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009). "123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma". J Nucl Med. 50 (8): 1237–43. doi:10.2967/jnumed.108.060467. PMID 19617326.